Mesothelioma UK is delighted to welcome Professor Kevin Blyth to its Board of Trustees. Kevin is Professor of Respiratory Medicine at the University of Glasgow and has a wealth of experience and knowledge of mesothelioma treatment and research and will make a fantastic addition to the board.
Kevin is a group leader at the CRUK Beatson Institute and leads the Glasgow Pleural Disease Unit based at the Queen Elizabeth University Hospital. He founded and is Director of the Macmillan Scottish Mesothelioma Network, which coordinates clinical care and trials for mesothelioma patients in Scotland. He is an NHS Scotland Research (NRS) Senior Research Fellow and leads a translational research programme focused on pleural disease, and in particular, mesothelioma.
He was Chief Investigator of the DIAPHRAGM study, which was the largest prospective biomarker study ever performed in mesothelioma. He is also Chief Investigator of the PREDICT-Meso (Pre-malignant drivers combined with target-drug validation in mesothelioma) International Accelerator Network which brings together expert centres from the UK, Spain, Italy, Belgium, US and Canada to deliver five integrated work-packages, generate new knowledge, new pre-clinical and clinical tools and ultimately new therapies ready for human trials.
Kevin has recently been elected Chair of the European Respiratory Society Pleural Malignancy Group and has excellent clinical and translational research links.
In addition to his years of experience, Kevin already has a well established and productive working relationship with Mesothelioma UK and will be an asset to the board, helping the charity to reach its goals of improving treatment and care for mesothelioma patients.
